TXNIP and metabolic dysfunction-associated steatotic liver disease: Furthermore, research on a high-fat diet-induced rat model of NAFLD revealed that Sal A significantly decreases the expression of TXNIP and inhibits the activation of the NLRP3 inflammasome and the nuclear translocation of ChREBP, indicating that Sal A’s protective effects on rat NAFLD are mediated through the modulation of the TXNIP-NLRP3 and TXNIP-ChREBP pathways [57].